<?xml version="1.0" encoding="UTF-8"?>
<p id="P20">Safety was assessed by TEAE reporting, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Patients were followed for TEAEs for 28 days after their last CC-486 dose.</p>
